文献速递血脂与心血管预防冠心病

老年人心血管病一级预防:阿司匹林与他汀治疗

Aspirin and statin therapy for primary prevention of cardiovascular disease in older adults.
PubMed 文献 · Heart · 2022-06-24

本文综述≥75岁老年人CVD一级预防中阿司匹林与他汀的价值。关键试验入组不足致证据缺乏;阿司匹林不再推荐常规使用,他汀可能有效但获益亚组不明且指南不一。认知障碍、功能受损和多药共存影响决策,需结合预期寿命和共享决策。

要点

  • 阿司匹林不推荐用于老年人CVD一级预防常规使用。
  • 他汀可能有效,但获益最大亚组不明且指南存在分歧。
  • 决策应结合共病、多药共存和预期寿命,而非仅绝对风险。

核心结论

  • 老年人CVD一级预防的价值取决于潜在终生获益,需个体化评估。

研究设计与样本

  • 综述,聚焦≥75岁老年人CVD一级预防,指出关键试验入组不足致证据缺乏。

主要发现

  • 阿司匹林不再推荐用于老年人CVD一级预防常规使用。
  • 他汀可能有效,但获益最大亚组不明且指南不一。
  • 基线衰弱可能影响他汀疗效,有主张去处方化。
  • 他汀与功能衰退证据混合,需警惕多药共存下不良反应。
  • 阿司匹林未显示影响认知或功能衰退,对基线认知障碍或衰弱者亦无效。

临床怎么用

  • 不应仅基于绝对风险决策,需考虑共病、多药共存和预期寿命。
  • 冠状动脉钙化评分和经老年人验证的风险分层工具可辅助评估获益。
  • 共享决策是复杂治疗决策的重要框架。

局限性

  • 老年人关键试验入组不足,证据质量有限。
  • 他汀与功能衰退证据混合,获益亚组不明。
  • 指南间存在分歧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The value of primary preventative therapies for cardiovascular disease (CVD) in older adults (age ≥75 years) is less certain than in younger patients. There is a lack of quality evidence in older adults due to underenrolment in pivotal trials. While aspirin is no longer recommended for routine use in primary prevention of CVD in older adults, statins may be efficacious. However, it is unclear which patient subgroups may benefit most, and guidelines differ between expert panels. Three relevant geriatric conditions (cognitive impairment, functional impairment and polypharmacy) may influence therapeutic decision making; for example, baseline frailty may affect statin efficacy, and some have advocated for deprescription in this scenario. Evidence regarding statins and incident functional decline are mixed, and vigilance for adverse effects is important, especially in the setting of polypharmacy. However, aspirin has not been shown to affect incident cognitive or functional decline, and its lack of efficacy extends to patients with baseline cognitive impairment or frailty. Ultimately, the utility of primary preventative therapies for CVD in older adults depends on potential lifetime benefit. Rather than basing treatment decisions on absolute risk alone, consideration of comorbidities, polypharmacy and life expectancy should play a significant role in decision making. Coronary calcium score and new tools for risk stratification validated in older adults that account for the competing risk of death may aid in evaluating potential benefits. Given the complexity of therapeutic decisions in this context, shared decision making provides an important framework.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Montgomery S, Miedema MD, Dodson JA, et al. Aspirin and statin therapy for primary prevention of cardiovascular disease in older adults. Heart. 2022. PMID: 34764212. doi:10.1136/heartjnl-2021-320154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。